Citations

Showing 10 of 108152 citations.

An under‐recognized phenomenon: Myocardial volume change during the cardiac cycle
Kumar, Vinayak , Rao, Chaitanya, Ryu, Alexander J. , Gibbons, Raymond J. , Chandrasekaran, Krishnaswamy , Asirvatham, Samuel J. , Araoz, Philip A. , Oh, Jae K. , Egbe, Alexander C. , Behfar, Atta , Anavekar, Nandan S., Behfar, Atta , Asirvatham, Samuel J , Kumar, Vinayak , Manduca, Armando , Ryu, Alexander J. , Gersh, Bernard J. , Borlaug, Barry A.

Mayo Clinic

Echocardiography | June 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/echo.15093 | PMID 34085722 Get It

Quantitative Shear Wave Speed Assessment for Muscles With the Diagnosis of Taut Bands and/or Myofascial Trigger Points Using Probe Oscillation Shear Wave Elastography: A Pilot Study
Lok, U‐Wai , Zhou, Chenyun , Tang, Shanshan , Madson, Timothy J., Gay, Ralph E. , Chen, Shigao , Yang, Lulu, Ling, Wenwu, Gong, Ping , Lok, U-Wai , Huang, Chengwu , Yang, Lulu , Ling, Wenwu , Gong, Ping , Jensen, Mark A.

Mayo Clinic

Journal of Ultrasound in Medicine | June 4, 2021 | Volume: 41 | Issue: 4 | Pages: 845-854

10.1002/jum.15764 | PMID 34085301 Get It

ObjectiveTo use probe oscillation shear wave elastography (PROSE) with two vibration sources to generate two shear waves in the imaging plane to quantitatively assess the shear wave speeds (SWSs) of muscles with and without the diagnosis of taut bands (TB) and/or myofascial trigger points (MTrPs).MethodsThirty‐three patients were scanned with the PROSE technique. Shear waves were generated through continuous vibration of the ultrasound probe, while the shear wave motions were detected using the same probe. SWSs for the sides with and without TBs and/or MTrPs were computed and compared. The pressure pain thresholds (PPTs) were measured as an indicator of maximum pain tolerance of patients. The statistical differences between the SWSs with and without TBs and/or MTrPs with different PPT values were analyzed using the nonparametric Wilcoxon rank‐sum test.ResultsThe mean SWSs for the sides with TBs and/or MTrPs are faster than that of the contralateral side without TBs and/or MTrPs. A significant difference was observed between mean SWSs with and without TBs and/or MTrPs without any information of PPT, with rank‐sum test P < .005. Additionally, with the information of PPT, a significant difference was observed between mean SWSs for the sides with and without TBs and/or MTrPs, for PPT values between 0 and 50 N/cm2 (P < .005), but for PPT values between 50 and 90 N/cm2, it was difficult to differentiate mean SWSs with and without TBs and/or MTrPs.ConclusionOur preliminary results show that SWSs measured from patients had a significant difference between the mean SWSs with and without TBs and/or MTrPs.
A novel ferroptosis phenotype‐related clinical‐molecular prognostic signature for hepatocellular carcinoma
Deng, Tuo , Hu, Bingren, Chen, Jin , Tong, Yifan , Zhao, Jungang , Shi, Zhehao , Deng, Liming , Chen, Gang , Wang, Yi , Chen, Gang , Wang, Yi , Zhang, Tan , Sun, Zhifu

Mayo Clinic

Journal of Cellular and Molecular Medicine | June 4, 2021 | Volume: 25 | Issue: 14 | Pages: 6618-6633

10.1111/jcmm.16666 | PMID 34085405 Get It

AbstractFerroptosis is a newly identified cell death mechanism and potential biomarker for hepatocellular carcinoma (HCC) therapy; however, its clinical relevance and underlying mechanism remain unclear. In this study, transcriptome and methylome data from 374 HCC cases were investigated for 41 ferroptosis‐related genes to identify ferroptosis activity‐associated subtypes. These subtypes were further investigated for associations with clinical and pathological variables, gene mutation landscapes, deregulated pathways and tumour microenvironmental immunity. A gene expression signature and predictive model were developed and validated using an additional 232 HCC cases from another independent cohort. Two distinct ferroptosis phenotypes (Ferroptosis‐H and Ferroptosis‐L) were identified according to ferroptosis gene expression and methylation in the patients with HCC. Patients with the Ferroptosis‐H had worse overall and disease‐specific survival, and the molecular subtypes were significantly associated with different clinical characteristics, mRNA expression patterns, tumour mutation profiles and microenvironmental immune status. Furthermore, a 15‐gene ferroptosis‐related prognostic model (FPM) for HCC was developed and validated which demonstrated accurate risk stratification ability. A nomogram included the FPM risk score, ECOG PS and hepatitis B status was developed for eventual clinical translation. Our results suggest that HCC subtypes defined by ferroptosis gene expression and methylation may be used to stratify patients for clinical decision‐making.
Association of a Remote Patient Monitoring (RPM) Program With Reduced Hospitalizations in Cancer Patients With COVID-19
Pritchett, Joshua C. , Desai, Aakash , Xie, Zhuoer , Saliba, Antoine N. , Leventakos, Konstantinos , Coffey, Jordan , Pearson, Kristina K., Speicher, Leigh L. , Orenstein, Robert , Virk, Abinash , Haddad, Tufia C. , Saliba, Antoine N. , Borah, Bijan J. , Desai, Aakash P , Xie, Zhuoer , Saliba, Antoine N , Coffey, Jordan D, Ganesh, Ravindra , Paludo, Jonas , Halfdanarson, Thorvardur R , Haddad, Tufia C , Pritchett, Joshua , Saliba, Antoine N , Coffey, Jordan D , Ganesh, Ravindra , Paludo, Jonas , Hálfdánarson, Þorvarður R.

Mayo Clinic

JCO Oncology Practice | June 4, 2021 | Volume: 17 | Issue: 9 | Pages: e1293-e1302

10.1200/op.21.00307 | PMID 34085535 Get It

PURPOSE: The goal of this study was to assess the impact of an interdisciplinary remote patient monitoring (RPM) program on clinical outcomes and acute care utilization in cancer patients with COVID-19. METHODS: This is a cross-sectional analysis following a prospective observational study performed at Mayo Clinic Cancer Center. Adult patients receiving cancer-directed therapy or in recent remission on active surveillance with polymerase chain reaction–confirmed SARS-CoV-2 infection between March 18 and July 31, 2020, were included. RPM was composed of in-home technology to assess symptoms and physiologic data with centralized nursing and physician oversight. RESULTS: During the study timeframe, 224 patients with cancer were diagnosed with COVID-19. Of the 187 patients (83%) initially managed in the outpatient setting, those who did not receive RPM were significantly more likely to experience hospitalization than those receiving RPM. Following balancing of patient characteristics by inverse propensity score weighting, rates of hospitalization for RPM and non-RPM patients were 2.8% and 13%, respectively, implying that the use of RPM was associated with a 78% relative risk reduction in hospital admission rate (95% CI, 54 to 102; P = .002). Furthermore, when hospitalized, these patients experienced a shorter length of stay and fewer prolonged hospitalizations, intensive care unit admissions, and deaths, although these trends did not reach statistical significance. CONCLUSION: The use of RPM and a centralized virtual care team was associated with a reduction in hospital admission rate and lower overall acute care resource utilization among cancer patients with COVID-19.
Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality
Senefeld, Jonathon W. , Klassen, Stephen A. , Wright, R. Scott , Joyner, Michael J. , Carter, Rickey E. , Casadevall, Arturo , Carter, Rickey E , Joyner, Michael J , Senefeld, Jonathon W , Klassen, Stephen A , Casadevall, Arturo , Dragotakes, Quigly , Johnson, Patrick W. , Paneth, Nigel

Mayo Clinic

eLife | June 4, 2021 | Volume: 10 | Issue: No issue available | Pages: No page available

10.7554/elife.69866 | PMID 34085928 Get It

Background: The US Food and Drug Administration authorized COVID-19 convalescent plasma (CCP) therapy for hospitalized COVID-19 patients via the Expanded Access Program (EAP) and the Emergency Use Authorization (EUA), leading to use in about 500,000 patients during the first year of the pandemic for the USA. Methods: We tracked the number of CCP units dispensed to hospitals by blood banking organizations and correlated that usage with hospital admission and mortality data. Results: CCP usage per admission peaked in Fall 2020, with more than 40% of inpatients estimated to have received CCP between late September and early November 2020. However, after randomized controlled trials failed to show a reduction in mortality, CCP usage per admission declined steadily to a nadir of less than 10% in March 2021. We found a strong inverse correlation (r = −0.52, p=0.002) between CCP usage per hospital admission and deaths occurring 2 weeks after admission, and this finding was robust to examination of deaths taking place 1, 2, or 3 weeks after admission. Changes in the number of hospital admissions, SARS-CoV-2 variants, and age of patients could not explain these findings. The retreat from CCP usage might have resulted in as many as 29,000 excess deaths from mid-November 2020 to February 2021. Conclusions: A strong inverse correlation between CCP use and mortality per admission in the USA provides population-level evidence consistent with the notion that CCP reduces mortality in COVID-19 and suggests that the recent decline in usage could have resulted in excess deaths. Funding: There was no specific funding for this study. AC was supported in part by RO1 HL059842 and R01 AI1520789; MJJ was supported in part by 5R35HL139854. This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority under Contract No. 75A50120C00096.
Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
Chen, Xiaoji , Hubbell, Earl , Kurtzman, Kathryn N. , Oxnard, Geoffrey R. , Venn, Oliver, Melton, Collin, Shaknovich, Rita , Ma, Ting , Meixiong, Gerry, Seiden, Michael V., Klein, Eric A. , Fung, Eric T. , Liu, Minetta C. , Hubbell, Earl , Kurtzman, Kathryn N , Klein, Eric A , Liu, Minetta , Zhao, Dong , Clarke, Christina A.

Mayo Clinic

Clinical Cancer Research | June 4, 2021 | Volume: 27 | Issue: 15 | Pages: 4221-4229

10.1158/1078-0432.ccr-21-0417 | PMID 34088722 Get It

Abstract Purpose: We recently reported the development of a cell-free DNA (cfDNA) targeted methylation (TM)-based sequencing approach for a multi-cancer early detection (MCED) test that includes cancer signal origin prediction. Here, we evaluated the prognostic significance of cancer detection by the MCED test using longitudinal follow-up data. Experimental Design: As part of a Circulating Cell-free Genome Atlas (CCGA) substudy, plasma cfDNA samples were sequenced using a TM approach, and machine learning classifiers predicted cancer status and cancer signal origin. Overall survival (OS) of cancer participants in the first 3 years of follow-up was evaluated in relation to cancer detection by the MCED test and clinical characteristics. Results: Cancers not detected by the MCED test had significantly better OS (P &lt; 0.0001) than cancers detected, even after accounting for other covariates, including clinical stage and method of clinical diagnosis (i.e., standard-of-care screening or clinical presentation with signs/symptoms). Additionally, cancers not detected by the MCED test had better OS than was expected when data were adjusted for age, stage, and cancer type from the Surveillance, Epidemiology, and End Results (SEER) program. In cancers with current screening options, the MCED test also differentiated more aggressive cancers from less aggressive cancers (P &lt; 0.0001). Conclusions: Cancer detection by the MCED test was prognostic beyond clinical stage and method of diagnosis. Cancers not detected by the MCED test had better prognosis than cancers detected and SEER-based expected survival. Cancer detection and prognosis may be linked by the underlying biological factor of tumor fraction in cfDNA.
Chronic versus episodic migraine: The 15‐day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency
Ishii, Ryotaro , Lalvani, Nim, Craven, Audrey, Goadsby, Peter J. , Silberstein, Stephen D., Burish, Mark J. , Dodick, David W , Goadsby, Peter J , Schwedt, Todd J. , Dumkrieger, Gina , Lipton, Richard B. , Olesen, Jes , Dodick, David W.

Mayo Clinic

Headache: The Journal of Head and Face Pain | June 4, 2021 | Volume: 61 | Issue: 7 | Pages: 992-1003

10.1111/head.14154 | PMID 34081791 Get It

Abstract Objective To evaluate whether the 15‐day threshold of headache days per month adequately reflects substantial differences in disability across the full spectrum of migraine. Background The monthly frequency of headache days defines migraine subtypes and has crucial implications for epidemiological and clinical research as well as access to care. Methods The patients with migraine ( N = 836) who participated in the American Registry for Migraine Research, which is a multicenter, longitudinal patient registry, between February 2016 and March 2020, were divided into four groups based on monthly headache frequency: Group 1 (0–7 headache days/month, n = 286), Group 2 (8–14 headache days/month, n = 180), Group 3 (15–23 headache days/month, n = 153), Group 4 (≥24 headache days/month, n = 217). Disability (MIDAS), Pain intensity (NRS), Work Productivity and Activity Impairment (WPAI), Pain Interference (PROMIS‐PI), Patient Health Questionnaire‐4 (PHQ‐4), and General Anxiety Disorder‐7 (GAD‐7) scores were compared. Results Mean (standard deviation [SD]) age was 46 (13) years (87.9% [735/836] female). The proportion of patients in each group was as follows: Group 1 (34.2% [286/836]), Group 2 (21.5% [180/836]), Group 3 (18.3% [153/836]), and Group 4 (26.0% [217/836]). There were significant relationships with increasing disability, lost productive time, and pain interference in higher headache frequency categories. There were no significant differences between Group 2 and Group 3 for most measures (NRS, all WPAI scores, PROMIS‐PI, GAD‐7, and PHQ‐4), although MIDAS scores differed (median [interquartile range (IQR)]; 38 [20–58] vs. 55 [30–90], p < 0.001). Patients in Group 1 had significantly lower MIDAS (median [IQR];16 [7–30], p < 0.001), WPAI‐% total active impairment (mean (SD): Group 1 [30.9 (26.8)] vs. Group 2 [39.2 (24.5), p = 0.017], vs. Group 3 [45.9 (24.1), p < 0.001], vs. Group 4 [55.3 (23.0), p < 0.001], and PROMIS‐PI‐T score (Group 1 [60.3 (7.3)] vs. Group 2 [62.6 (6.4), p = 0.008], vs. Group 3 [64.6 (5.6), p < 0.001], vs. Group 4 [66.8 (5.9), p < 0.001]) compared to all other groups. Patients in Group 4 had significantly higher MIDAS (median (IQR): Group 4 [90 (52–138)] vs. Group 1 [16 (7–30), p < 0.001], vs. Group 2 [38 (20–58), p < 0.001], vs. Group 3 [55 (30–90), p < 0.001], WPAI‐%Presenteeism (Group 4 [50.4 (24.4)] vs. Group 1 [28.8 (24.9), p < 0.001], vs. Group 2 [34.9 (22.3), p < 0.001], vs. Group 3 [40.9 (22.3), p = 0.048], WPAI‐% total work productivity impairment (Group 4 [55.9 (26.1)] vs. Group 1 [32.1 (37.6), p < 0.001], vs. Group 2 [38.3 (24.0), p < 0.001], vs. Group 3 [44.6 (24.4), p = 0.019]), and WPAI‐%Total activity impairment (Group 4 [55.3 (23.0)] vs. Group 1 [30.9 (26.8), p < 0.001], vs. Group 2 [39.2 (24.5), p < 0.001], vs. Group 3 [45.9 (24.1), p = 0.025]) scores compared with all other groups. Conclusion Our data suggest that the use of a 15 headache day/month threshold to distinguish episodic and chronic migraine does not capture the burden of illness nor reflect the treatment needs of patients. These results have important implications for future refinements in the classification of migraine.
The Role of Sonography in a Rare Case of Hepatic Artery Pseudoaneurysm: A Case Study Report
Chupka, Nadia M. , Atwell, Thomas D. , McPhail, Ian R., Hunt, Talisha M.

Mayo Clinic

Journal of Diagnostic Medical Sonography | June 4, 2021 | Volume: 37 | Issue: 5 | Pages: 500-505

10.1177/87564793211018971 Get It

Hepatic artery pseudoaneurysms (HAPs) are rare, life-threatening complications that arise in response to liver trauma or underlying inflammatory processes. The risk of rupture necessitates prompt diagnosis and treatment. Sonography is an important imaging modality used to evaluate and characterize suspected HAPs. In the case described below, sonography played an important role in the diagnosis and successful treatment of a patient with a large, high-risk HAP.
The Effectiveness of Identifying Primary Gallbladder Adenocarcinoma Utilizing Contrast-Enhanced Ultrasound: A Case Report
Hunt, Talisha M. , Waletzko, Michelle R., Knudsen, John M. , Atwell, Thomas D. , Chupka, Nadia M.

Mayo Clinic

Journal of Diagnostic Medical Sonography | June 4, 2021 | Volume: 37 | Issue: 6 | Pages: 575-583

10.1177/87564793211018959 Get It

Gallbladder carcinoma is rare and difficult to detect in the early stages of the disease process, due to lack of symptoms. Sonography is typically the first modality of choice for assessing gallbladder pathology due to its high sensitivity, portability, real-time imaging capability, and non-ionizing technique. Conventional gray-scale and color Doppler sonographic imaging may be ambiguous for diagnosing solid tumors, such as gallbladder carcinoma. In this case, gallbladder carcinoma was definitively diagnosed utilizing contrast-enhanced ultrasound, allowing for quick patient treatment options and an optimal surgical outcome.
Prevalence and Impact of Obesity on Disease-specific Outcomes in a Population-based Cohort of Patients with Ulcerative Colitis
Johnson, Amanda M. , Harmsen, William S. , Tremaine, William J., Loftus, Edward V. , Aniwan, Satimai , Loftus, Edward V , Dayyeh, Barham K. Abu

Mayo Clinic

Journal of Crohn's and Colitis | June 4, 2021 | Volume: 15 | Issue: 11 | Pages: 1816-1823

10.1093/ecco-jcc/jjab097 | PMID 34117877 Get It

Abstract Background and Aims There remains a historical misconception that inflammatory bowel disease [IBD] patients are underweight. However, recent data suggest rates of obesity in IBD parallel to those of the general population. The impact obesity has on the natural history of IBD is unclear. We aimed to determine obesity rates at the time of IBD diagnosis in a population-based cohort of ulcerative colitis [UC] patients. Methods Chart review was performed on patients diagnosed with UC over 1970–2010. Data were collected on demographics, body mass index [BMI], disease characteristics, IBD-specific hospitalisations, intestinal resection, and corticosteroid use. The proportion of patients who were obese at the time of their diagnosis was evaluated over time, and survival free of IBD-related complications was assessed using Kaplan-Meier survival analysis. Results A total of 417 adults were diagnosed with UC over 1970–2010, 55.4% of whom were classified as either overweight [34.8%] or obese [20.6%]. The prevalence of obesity increased 2–3-fold over the 40-year study period. Obese patients had a 72% increased risk of hospitalisation (hazard ratio [HR],1.72; 95% confidence interval [CI], 1.10–2.71; p = 0.018) when compared with normal weight patients. Additionally, with each incremental increase in BMI by 1 kg/m2, the risk of hospitalisation increased by 5% [HR,1.05; 95% CI, 1.01–1.08; p = 0.008] and risk of corticosteroid use increased by 2.6% [HR,1.026; 95% CI, 1.00–1.05; p = 0.05]. Conclusions The prevalence of obesity in the UC population is increasing and may have negative prognostic implications, specifically regarding risk of future hospitalisation and corticosteroid use. Additional prospective studies are necessary to more clearly define these associations.